middle.news
Avecho restarts final Phase III insomnia trial recruitment after positive interim review
9:15am on Monday 31st of August, 2026 AEST
•
Healthcare
Read Story
Avecho restarts final Phase III insomnia trial recruitment after positive interim review
9:15am on Monday 31st of August, 2026 AEST
Key Points
Recruitment recommences for final cohort in Phase III insomnia trial
Independent board endorses original 519-participant target after interim analysis
No serious adverse events reported among 244 participants assessed
Additional clinical sites to accelerate enrolment aiming for 12-month completion
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Avecho Biotechnology (ASX:AVE)
OPEN ARTICLE